Multiple myeloma (MM) is a cancer of plasma cells originating in the bone marrow. Different stages of MM include “Refractory myeloma” which is non-responsive to therapy or progresses within 60 days of the last line of therapy; “Relapsed myeloma” in which previously treated myeloma progresses after prior therapy and requires new therapy; and “Relapsed and refractory multiple myeloma (RRMM)” is disease that is nonresponsive to the chosen line of therapy in patients who had achieved a minimal response or better at some point previously in their disease. Our client aimed to understand how different drugs impact RRMM patients, especially surrounding clinical efficacy of the drugs (survival and response rates), their impact on the quality of life, and their economic outcomes, in both controlled as well as real-world settings. To address this requirement, we screened around 600 records to identify the most relevant publications, and extracted data from nearly 200 records.
Therapy area: Oncology, Hematology
#MarksManInsights
Relapsed or refractory multiple myeloma (RRMM): efficacy and safety of available therapies
by